CARSGEN-B (02171) saw its share price jump more than 32% after announcing its financial results. As of the latest update, the stock had risen by 32.48%, trading at HK$14.40 with a turnover of HK$47.71 million.

On March 6, CARSGEN-B released its annual results for the period ending December 31, 2025. The company reported revenue of RMB 126 million, representing a year-on-year increase of 218.7%. The loss attributable to owners of the parent narrowed by 87.7% to RMB 97.861 million. Basic loss per share was RMB 0.18. For the fiscal year ending December 31, 2025, the group's revenue was primarily derived from its product CytoCART® (an autologous BCMA CAR-T cell therapy). Notably, the revenue from CytoCART® was calculated based on the ex-factory price rather than the end-market price.